Aller au contenu
Skip to content
Peptide Stacks

Melanotan II & PT-141 Stack Dosage Protocol

Melanocortin agonists — Melanotan II (tanning) + PT-141/bremelanotide (libido). Two separate vials; combination not clinically validated.

Peptide Stacks Updated November 25, 2025 7 min read Research information only
Melanotan II & PT-141 Stack Dosage Protocol
Why researchers study it

Why Melanotan II + PT-141 draws research interest

These are the directions researchers and the peptide community most often explore Melanotan II + PT-141 for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.

Libido & sexual function

PT-141/bremelanotide is FDA-approved as Vyleesi for hypoactive sexual desire disorder; investigated for sexual arousal pathways.

Tanning & skin pigmentation

Melanotan II is investigated in research on melanogenesis and UV-independent skin pigmentation; not an approved tanning agent.

Appetite & food intake

Melanocortin agonists like Melanotan II are studied preclinically for effects on appetite and food intake in animal models.

Melanocortin receptor signaling

Both are researched as melanocortin receptor agonists to explore MC1R–MC4R pathways; the combination is not clinically validated.

Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.

Reconstitution calculator

Mix & measure Melanotan II + PT-141 · 20 mg

Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.

Concentration—mg/mL
Draw volume—mL
On the syringe—units
Doses / vial— 

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →

Ask what generic AI won't
ChatGPT dodges your Melanotan II + PT-141 dosing questions. OpenPeptide answers them.
Documented protocols, exact reconstitution math, and real sources — no lectures, no dead ends.
Quick answerIn the research literature, the 10+10 mg Melanotan II + PT-141 stack vials are typically each reconstituted with 3 mL of bacteriostatic water, and documented research protocols reference 250 mcg per dose from the resulting solution. These values reflect reference protocols only and are provided strictly for research use, not human use.

Fixed ratio: Melanotan II 10 mg : PT-141 10 mg — a 1:1 blend. Every withdrawal keeps that ratio, so the components cannot be dosed independently.

01 · Dosing & reconstitution

Dosing & Reconstitution Guide

Two separate vials, dosed independently — reconstitute and measure each peptide on its own

ℹ

Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Melanotan II (10 mg vial) — Gradual Tanning Build (3 mL = 3.33 mg/mL)

▪

Reconstitute: Add 3 mL bacteriostatic water to the 10 mg vial → 3.33 mg/mL. On a U-100 syringe, 1 unit ≈ 33 mcg.

▪

Weeks 1–2: 250 mcg (0.25 mg) per injection → ~7.5 units (0.075 mL), 2× per week.

▪

Weeks 3–4: 500 mcg (0.5 mg) per injection → ~15 units (0.15 mL), 2× per week.

▪

Note: Early doses are under 10 units — a 30-unit insulin syringe improves accuracy. Build gradually over the 4-week cycle to limit nausea and flushing.

PT-141 (10 mg vial) — On-Demand (1 mL = 10 mg/mL)

▪

Reconstitute: Add 1 mL bacteriostatic water to the 10 mg vial → 10 mg/mL. On a U-100 syringe, 1 unit = 0.1 mg (100 mcg).

▪

Female HSDD (Vyleesi-equivalent): 1.75 mg → ~18 units (0.18 mL), as needed at least 45 min before activity[1].

▪

Male ED (off-label, not FDA-approved): 1–2 mg → 10–20 units (0.10–0.20 mL), 30–60 min before activity.

▪

Limits: Maximum one dose per 24 hours and no more than 8 per month. Alternatively, some references split into 1 mg (10 units) twice weekly.

ℹ

Reconstitution steps: Draw the bacteriostatic water into a sterile syringe and inject it slowly against the vial wall — do not shake. Swirl gently until dissolved, label each vial with the date, then refrigerate at 2–8 °C, protected from light.

02 · What you’ll need

Supplies Needed

Quantities below cover a 4-week Melanotan II tanning cycle plus on-demand PT-141 dosing. Each peptide is kept and injected separately.

✓Melanotan II (10 mg vial)

At 2×/week with a gradual 250–500 mcg build, one 10 mg vial covers roughly a full 4-week cycle.

  • 4-week cycle: ~1–2 vials
✓PT-141 (10 mg vial)

At ~1.75 mg per on-demand dose, one 10 mg vial covers roughly 5–8 doses (the monthly cap).

  • Per month: ~1 vial (≤ 8 doses)
✓Insulin Syringes (U-100, 1 mL)

A 30-unit syringe improves accuracy for the small Melanotan II doses; use a fresh syringe per injection.

  • Melanotan II: ~8 / cycle
  • PT-141: 1 per dose
✓Bacteriostatic Water & Swabs

3 mL per Melanotan II vial and 1 mL per PT-141 vial, plus two alcohol swabs (stopper + site) each injection.

  • Bac water: 1–2 bottles
  • Alcohol swabs: 1 box
PT-141 Vial
Peptide Vial

View Supplier

Insulin Syringes
Insulin Syringes

View Supplier

Bacteriostatic Water
Bacteriostatic Water

View Supplier

Alcohol Pads
Alcohol Pads

View Supplier

Stack Administration

Because each peptide has its own schedule, concentration and syringe, administer them independently.

  • ▪Melanotan II timing: Inject on two consistent days each week (for example Monday and Thursday) for the 4-week cycle.
  • ▪PT-141 timing: Use only before anticipated sexual activity — not on a fixed daily schedule.
  • ▪Same-day use: If both fall on one day, use separate sites and separate syringes; do not stack them in a single shot.
  • ▪Logs: Track each peptide’s dose, date and effects separately to keep the protocol consistent.

Storage Instructions

Correct storage preserves the stability of both peptides.

  • ▪Lyophilized: Keep both dry vials cold and dark until reconstitution, limiting moisture exposure.
  • ▪Reconstituted: Store both solutions at 2–8 °C (refrigerator), protected from light, and do not freeze the mixed solution.
  • ▪Handling: Let chilled vials reach room temperature before drawing, and keep solutions clear of heat and direct light.
  • ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of either reconstituted solution.
03 · Good to know

Important Notes

Safety and regulatory points that apply to this two-peptide stack.

  • ▪Never mix the vials: Use a fresh sterile U-100 syringe for each peptide and each injection; dispose of it in a sharps container.
  • ▪Melanotan II safety signals: Documented serious risks include melanoma and changes to moles, priapism, rhabdomyolysis, renal infarction and posterior reversible encephalopathy (PRES). It is approved nowhere and has drawn regulatory warning letters.
  • ▪PT-141 cautions: Can cause transient blood-pressure increase, nausea and flushing; observe the 1 / 24 h and ≤ 8 / month limits[4].
  • ▪Monitoring: Watch for nausea, facial flushing and blood-pressure changes, and have a dermatologist check any pigment or mole changes during Melanotan II use.
  • ▪Regulatory note: Only the finished drug Vyleesi (PT-141) is FDA-approved — for premenopausal women with HSDD. Research-grade PT-141, male/off-label use, and all Melanotan II use are not covered. Melanotan II is also caught by WADA category S0.
04 · How it works

How This Works

Both peptides act on the melanocortin receptor family, and PT-141 (bremelanotide) is in fact a metabolite-derived analogue of Melanotan II[1]. That shared origin is why they appear together — but they target different receptors and outcomes.

Melanotan II is a non-selective MC1R–MC5R agonist. Activation of MC1R in skin drives melanin synthesis (tanning), while central MC3R/MC4R activity is linked to its libido and appetite effects[5].

PT-141 (bremelanotide) is a more selective central MC4R agonist that acts in the brain to increase sexual desire and arousal, rather than acting on the genital vasculature like PDE5 inhibitors[1][3].

Approval status, plainly: PT-141 as the finished drug Vyleesi is FDA-approved (2019), but only for premenopausal women with HSDD. Research-grade PT-141 and any male or off-label use are not covered by that approval. Melanotan II is not approved anywhere — it is a research chemical with FDA warning letters and documented serious safety signals (melanoma, priapism, rhabdomyolysis, renal infarction, PRES).

The popular “tanning + libido synergy” framing for combining these peptides is not clinically validated. This page is for research and educational purposes only.

05 · Daily habits

Lifestyle Factors

Habits that support tolerability and reduce risk alongside the stack.

  • ▪Sun caution: Melanotan II does not replace sun protection — continue using sunscreen and avoid the assumption that a deeper tan means UV safety.
  • ▪Skin checks: Photograph and monitor moles; see a dermatologist for any new, changing or asymmetric lesions.
  • ▪Hydration & nutrition: Stay well hydrated and eat regularly, since nausea is a common early effect of both peptides.
  • ▪Blood pressure: If you are sensitive to blood-pressure changes, check it before and after PT-141 and avoid alcohol around dosing.
06 · What to expect

Potential Benefits & Side Effects

What the literature describes for each peptide. Only Vyleesi (PT-141) for female HSDD has FDA-level efficacy data; Melanotan II is unapproved.

Reported Effects

  • ▪Melanotan II — tanning: Increased melanin and a deeper tan with less sun exposure, via MC1R activation.
  • ▪PT-141 — libido: Increased sexual desire and arousal; for female HSDD this is supported by Vyleesi trial data[3].
  • ▪Not validated together: No trial supports combining the two for a tanning + libido “synergy.”

Side Effects & Risks

  • ▪Common: Nausea, facial flushing and headache with either peptide, often strongest early on.
  • ▪Melanotan II — serious: Melanoma and mole changes, priapism, rhabdomyolysis, renal infarction and PRES have been reported.
  • ▪PT-141: Transient blood-pressure increase and, rarely, focal hyperpigmentation with repeated use[4].
  • ▪Sport restriction: Melanotan II is caught by WADA category S0 (non-approved substances).
07 · Injection technique

Injection Technique

General subcutaneous technique, applied separately to each peptide, following established best-practice guidance[6].

Pre-Injection Preparation

  • ▪Wash your hands well with soap and water.
  • ▪Confirm you have the correct vial — Melanotan II (3.33 mg/mL) or PT-141 (10 mg/mL) — before drawing.
  • ▪Wipe the vial stopper and the chosen site (abdomen, thigh or upper arm) with separate alcohol swabs and let them air-dry.
  • ▪Draw the intended dose into the right syringe, then check for air bubbles and push any out.

Injection Procedure

  • ▪Pinch a skinfold at the chosen site between thumb and forefinger.
  • ▪Insert the needle at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[6].
  • ▪Skip aspiration for subcutaneous shots — it isn’t needed.
  • ▪Press the plunger slowly and steadily until it’s fully down.
  • ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.

Post-Injection Care

  • ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
  • ▪Return each reconstituted vial to the fridge right away.
  • ▪Rotate sites between injections to prevent irritation and lipohypertrophy.
  • ▪Watch each site for excess redness, swelling or signs of infection.
09 · The evidence

References

  1. 1
    FDA
    Bremelanotide (Vyleesi) prescribing information — dosing, indication (premenopausal HSDD), and use limitations.

    View Source ↗

  2. 2
    NCBI Bookshelf (LiverTox)
    Bremelanotide: mechanism as a melanocortin-4 receptor agonist, clinical use, and safety profile.

    View Source ↗

  3. 3
    PMC
    Bremelanotide for female hypoactive sexual desire disorder — phase-3 clinical trial review.

    View Source ↗

  4. 4
    Mayo Clinic
    Bremelanotide (subcutaneous route): side effects, precautions, and transient blood-pressure effects.

    View Source ↗

  5. 5
    PubMed
    Evaluation of Melanotan-II: pilot phase-I study and melanocortin receptor pharmacology (MC1R–MC5R).

    View Source ↗

  6. 6
    TGA Australia
    Safety alert — the serious health risks of unapproved Melanotan tanning products.

    View Source ↗

  7. 7
    Prime Lab Peptides
    PT-141 (10 mg) product page — purity specifications and certificates of analysis.

    View Source ↗

  8. 8
    Prime Lab Peptides
    Research peptides catalogue — sourcing and quality documentation.

    View Source ↗

Read the complete guide Peptide Dosage Chart Where to source it Which suppliers we lab-tested — purity, price and shipping compared
FAQ

Melanotan II + PT-141 — frequently asked questions

How do I reconstitute a 20 mg vial of Melanotan II + PT-141?

Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.

How much bacteriostatic water should I add to Melanotan II + PT-141?

There is no single correct amount — more water simply spreads the same 20 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.

What do the "units" on an insulin syringe mean?

On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.

How should I store Melanotan II + PT-141 after mixing?

Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.

How many doses does a 20 mg vial of Melanotan II + PT-141 provide?

Divide the vial strength of 20 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.

Is Melanotan II + PT-141 approved for human use?

No. Melanotan II + PT-141 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.

Stay precise

New protocols & dosing updates

Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.